

1 **¹⁸F-FDG-PET/CT as a diagnostic tool in native valve endocarditis**

2

3 Ilse J.E. Kouijzer, MD, PhD^{a,b}, Marvin A.H. Berrevoets, MD^a, Erik H.J.G. Aarntzen, MD, PhD^c, Janneke de
4 Vries, MD^d, Arie P.J. van Dijk, MD, PhD^e, Wim J.G. Oyen, MD, PhD^{c,f}, Lioe-Fee de Geus-Oei, MD, PhD^{b,g},
5 Chantal P. Bleeker-Rovers, MD, PhD^a

6

7 ^a Department of Internal Medicine and Infectious Diseases, Radboud university medical center, Nijmegen, the
8 Netherlands

9 ^b MIRA Institute for Biomedical Technology and Technical Medicine, Biomedical Photonic Imaging Group,
10 University of Twente, Enschede, the Netherlands

11 ^c Department of Radiology and Nuclear Medicine, Radboud university medical center, Nijmegen, the
12 Netherlands

13 ^d Department of Medical Microbiology, Radboud university medical center, Nijmegen, the Netherlands

14 ^e Department of Cardiology, Radboud university medical center, Nijmegen, the Netherlands

15 ^f Department of Nuclear Medicine, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust,
16 London, United Kingdom

17 ^g Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands

18

19 **Address for correspondence:**

20 Ilse J.E. Kouijzer

21 Department of Internal Medicine and Infectious Diseases, Radboud university medical center,

22 P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands.

23 E-mail: ilsekouijzer@gmail.com, telephone: 0031-24-3618819

24 **Conflict of interest and source of funding:** none.

25 **Running head:** FDG-PET/CT in native valve endocarditis

26 **Abstract**

27

28 **Objective**

29 The aim of the study is to investigate the value of ¹⁸F-fluorodeoxyglucose positron emission tomography
30 combined with computed tomography (¹⁸F-FDG-PET/CT) in diagnosing native valve endocarditis (NVE).

31 **Methods**

32 All patients with bacteremia and suspicion of NVE between January 2013 and June 2016 were identified from
33 the hospitals' register and retrospectively included if echocardiography and ¹⁸F-FDG-PET/CT were performed
34 within 14 days. ¹⁸F-FDG-PET/CT scans were scored independently by two nuclear medicine physicians. ¹⁸F-
35 FDG-PET/CT was compared to the modified Duke criteria and a multidisciplinary consensus.

36 **Results**

37 Eighty-eight patients were included. In 10 patients with definite NVE according to the modified Duke criteria, 3
38 patients (30.0%) had increased ¹⁸F-FDG uptake in or around the heart valves and 7 patients (70.0%) had no
39 increased ¹⁸F-FDG uptake. In patients without definite NVE according to the modified Duke criteria, 89.7%
40 (70/78) patients had no increased ¹⁸F-FDG uptake in or around the heart valves. **Of all 20 patients with NVE**
41 **according to multidisciplinary consensus, 9 patients (45.0%) had increased ¹⁸F-FDG uptake in or around the**
42 **heart valves and 11 patients (55.0%) had a normal ¹⁸F-FDG-PET/CT.**

43 **Conclusions**

44 A negative ¹⁸F-FDG-PET/CT result should not be interpreted as an exclusion of NVE. In patients with possible
45 or rejected NVE according to the modified Duke criteria, ¹⁸F-FDG-PET/CT could be used in case of sustained
46 suspicion of NVE due to its high specificity in case of abnormal FDG-uptake at the valve region. ¹⁸F-FDG-
47 PET/CT is important for detecting metastatic infection which already warrants the need to perform ¹⁸F-FDG-
48 PET/CT in all patients with suspected NVE.

49

50 **Key-words:** ¹⁸F-FDG-PET/CT; endocarditis; Duke criteria; native valve

51 **Introduction**

52

53 Infective endocarditis is a severe condition with a mortality rate up to 40% [1]. Early diagnosis of infective
54 endocarditis is essential for successful management and improved outcome, but diagnosing endocarditis is
55 challenging due to a variable clinical presentation with often nonspecific symptoms. For diagnosing infective
56 endocarditis the modified Duke criteria are currently used [2]. According to these criteria, diagnosis of definite
57 endocarditis is mainly based on positive blood cultures with typical micro-organisms and/or evidence of
58 infective endocarditis on echocardiography. However, sensitivity of echocardiography is limited, approximately
59 75% for transthoracic echocardiography (TTE) and 85% - 90% for transesophageal echocardiography (TEE) [3].

60

61 ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography combined with computed tomography (PET/CT)
62 has shown effectiveness in diagnosing infectious diseases. The value of ¹⁸F-FDG-PET/CT in diagnosing
63 infective endocarditis has been reported [4] and has shown to be a valuable diagnostic technique in patients
64 suspected of prosthetic valve endocarditis (PVE). Recently, ¹⁸F-FDG-PET/CT was added to the European
65 Society of Cardiology modified diagnostic criteria as a major criterion for PVE [5]. In patients with native valve
66 endocarditis (NVE), the diagnostic value of ¹⁸F-FDG-PET/CT has not been studied extensively. A few studies,
67 including often less than 10 patients with native valves, found low sensitivity for ¹⁸F-FDG-PET/CT in
68 diagnosing NVE [4]. However, these studies were often performed without prior low carbohydrate-fat allowed
69 diet to suppress cardiac glucose metabolism [6]. The purpose of this study was to investigate the diagnostic value
70 of ¹⁸F-FDG-PET/CT in NVE in a large cohort of patients, prepared with a low carbohydrate-fat allowed diet.

71 **Methods**

72

73 **Patients and study design**

74 All patients in this study were retrospectively included between January 2013 and June 2016 in the Radboud
75 university medical center, a tertiary referral center in Nijmegen, the Netherlands. Patients with bacteremia were
76 included when both echocardiography, because of suspicion of NVE (TTE and/or TEE), and ¹⁸F-FDG-PET/CT
77 were performed within 14 days. Exclusion criteria were an age below 18 years, prosthetic heart valve, cardiac
78 implantable electronic devices (CIED) infections, more than 14 days between ¹⁸F-FDG-PET/CT and
79 echocardiography, when no low carbohydrate-fat allowed diet was used prior to the ¹⁸F-FDG-PET/CT, and when
80 assessment of the heart was impossible due to physiological ¹⁸F-FDG uptake despite the low carbohydrate-fat
81 allowed diet. According to Dutch law, this study was exempt from approval by an ethics committee, because of
82 the retrospective character of this study and the anonymous storage of data. This was confirmed by the regional
83 ethics committee.

84

85 In all patients included in this study, the microbiologists advised for an infectious disease specialist consultation
86 because of the positive blood culture. All patients were discussed in a multidisciplinary 'endocarditis team',
87 including infectious disease specialists, medical microbiologists, cardiologists, and nuclear medicine physicians.
88 In this weekly multidisciplinary meeting, the medical history, physical examination, laboratory and
89 microbiological results, and imaging results including ¹⁸F-FDG-PET/CT of all patients were presented and based
90 on this clinical information a diagnosis was made. The diagnosis was not based on a scoring system but made by
91 consensus by all physicians present at the meeting based on all clinical signs and symptoms, risk factors, blood
92 cultures (number of positive cultures/total, micro-organism) and all imaging performed. For echocardiography,
93 TTE was used as a first-line screening technique. TEE was advocated in all patients in whom TTE was negative
94 for NVE, especially when imaging was hampered due to technical or anatomical problems. NVE was diagnosed
95 according to the modified Duke criteria [2] as gold standard and also to the multidisciplinary consensus. NVE
96 was treated according to international guidelines [5].

97

98 **Diagnostic work-up**

99 An integrated PET/CT scanner (Biograph 40 mCT; Siemens Healthcare) was used for imaging. Before ¹⁸F-FDG
100 injection, patients fasted and any glucose or insulin-containing infusions were discontinued for at least six hours.

101 All patients were instructed to adhere to a low carbohydrate-fat allowed diet 24 hours before ^{18}F -FDG-PET/CT
102 was performed. Blood glucose samples were taken from all patients prior to ^{18}F -FDG administration. At the time
103 of ^{18}F -FDG injection glucose was below 12 mmol/l in all patients. One hour after intravenous injection of an
104 average dosage of 3.3 MBq/kg ^{18}F -FDG (Mallinckrodt Pharmaceuticals, Petten, The Netherlands or IBA
105 Molecular, Amsterdam, The Netherlands), a whole-body low-dose CT scan was acquired for anatomic
106 correlation and attenuation correction of the PET data. Emission images of the same area were acquired. Images
107 of the heart were re-evaluated independently by two nuclear medicine physicians without knowledge of prior
108 clinical evaluation. When it was not possible to reliably evaluate the valve planes, patients were excluded. Any
109 increased ^{18}F -FDG uptake in or around the heart valves outside the area of the myocardium was considered as
110 abnormal. Minimally increased ^{18}F -FDG uptake was defined as uptake in the region of a heart valve just above
111 normal heart uptake. Highly increased ^{18}F -FDG uptake of a heart valve was defined as uptake in the region of the
112 heart valve clearly distinguishable from normal heart uptake. When uptake in the region of a heart valve was not
113 distinguishable from normal heart uptake, ^{18}F -FDG uptake was considered negative. Subsequently, discordant
114 results were solved by consensus reading.

115

116 Echocardiography was considered positive for infective endocarditis when vegetations, defined as oscillating
117 intracardiac structures, were visualized on the valves or their adjacent structures or in the path of a regurgitant jet
118 in the absence of an alternative anatomic explanation.

119

120 **Statistical analysis**

121 In patients with definite NVE according to the modified Duke criteria, any comparison was made with patients
122 with possible and rejected NVE according to the modified Duke criteria. The kappa statistic test was used to
123 calculate the level of agreement between the two nuclear medicine physicians. Differences in outcomes were
124 tested using Fisher's exact test for categorical variables. Statistical significance was defined as a *p* value less than
125 0.05. Statistical analysis was performed using SPSS (version 22.0;SPSS, Inc.).

126 **Results**

127

128 A total of 104 patients underwent both echocardiography and ¹⁸F-FDG-PET/CT within 14 days because of
129 bacteremia. Sixteen patients were excluded because ¹⁸F-FDG-PET/CT scan quality was too limited for
130 assessment of the heart region because of physiological ¹⁸F-FDG uptake. Of all 88 included patients, baseline
131 characteristics are shown in Table 1. Ten patients (11.4%) were diagnosed with definite NVE and 48 patients
132 (54.5%) were diagnosed with possible NVE according to the modified Duke criteria. In 30 patients, diagnosis of
133 NVE was rejected (34.1%). The evaluation of ¹⁸F-FDG-PET/CT for NVE showed a high level of agreement
134 (Cohen's kappa 0.97).

135

136 **Definite NVE**

137 In 10 patients with definite NVE according to the modified Duke criteria, 3 patients (30.0%) had increased ¹⁸F-
138 FDG uptake in or around the heart valves. Seven patients (70.0%) had no increased ¹⁸F-FDG uptake in or around
139 the heart valves. In patients without definite NVE according to the modified Duke criteria, 89.7% (70/78)
140 patients had no increased ¹⁸F-FDG uptake in or around the heart valves. In all patients with definite NVE
141 according to the modified Duke criteria and with increased ¹⁸F-FDG uptake at the heart valve region, ¹⁸F-FDG
142 uptake was highly increased.

143

144 **Possible NVE**

145 Of all 48 patients with possible NVE according to the modified Duke criteria, 5 patients (10.4%) had increased
146 ¹⁸F-FDG uptake in or around the heart valves. Although these 5 patients had only possible NVE according to the
147 modified Duke criteria, 3 of these patients (60.0%) were treated as having NVE based on the severity of
148 infection, risk factors, and ¹⁸F-FDG-PET/CT results (Fig. 1). Of 43 patients with possible NVE according to the
149 modified Duke criteria without increased ¹⁸F-FDG uptake in the heart valve region, 4 patients (9.3%) were
150 treated as having NVE.

151

152 **Rejected NVE**

153 In 3 patients with increased ¹⁸F-FDG uptake in the heart valve region, NVE was rejected according to the Duke
154 criteria. One patient was treated for 2 years until his death for an infected abdominal aortic graft with *E. coli* and
155 *C. albicans*. Another patient was treated for 6 months until her death for an infected thoracic aortic aneurysm

156 with *Salmonella dublin*. One patient was treated for 6 weeks because of *S. aureus* bacteremia with metastatic
157 foci in lungs and soft tissue. She died 6 months later due to duodenum carcinoma.

158

159 **Multidisciplinary consensus**

160 NVE was diagnosed according to the multidisciplinary consensus in 20 patients (22.7%) (Fig 2). Of all patients
161 with NVE according to the multidisciplinary consensus, 9 patients (45.0%) had increased ¹⁸F-FDG uptake in or
162 around the heart valves and 11 patients (55.0%) had normal ¹⁸F-FDG-PET/CT. Of the 20 patients with definite
163 NVE according to the multidisciplinary consensus, 10 were initially classified as definite, 7 as possible, and 3 as
164 rejected endocarditis by the modified Duke criteria. In patients with increased ¹⁸F-FDG uptake in or around the
165 heart valves, metastatic infection other than endocarditis was found in 72.7% (8/11) of patients and in patients
166 without increased ¹⁸F-FDG uptake in or around the heart valves metastatic infection was found in 51.9% (40/77)
167 of patients ($p = 0.195$). No relapses occurred.

168

169 Classification of all patients according to the diagnosis of NVE based on the modified Duke criteria, modified
170 Duke criteria including ¹⁸F-FDG-PET/CT result as a major criterion, ¹⁸F-FDG-PET/CT result only, and
171 diagnosis according to the multidisciplinary consensus are shown in Table 2.

172

173 **Metastatic infection**

174 ¹⁸F-FDG-PET/CT detected metastatic infection other than endocarditis in 48 patients (54.5%). ¹⁸F-FDG-PET/CT
175 was the first modality to localize infectious foci in 38 patients (79.2%). Localizations of these metastatic
176 infection were endovascular infection (23.7%), spondylodiscitis (23.7%), pulmonary foci (15.8%), arthritis
177 (13.2%), soft tissue infections (13.2%), splenic abscesses (7.9%), and non-vertebral osteomyelitis (2.6%).

178 **Discussion**

179

180 Data on the value of ¹⁸F-FDG-PET/CT in NVE is limited. This is the first study in a large cohort investigating
181 the value of ¹⁸F-FDG-PET/CT in patients with suspected NVE only, by excluding PVE and CIED infections.
182 Our study shows that ¹⁸F-FDG-PET/CT has a low sensitivity with 7 out of 10 patients with definite NVE
183 according to the modified Duke criteria without increased ¹⁸F-FDG uptake of the heart valve. Although ¹⁸F-
184 FDG-PET/CT is insufficient to rule out NVE, a positive finding on ¹⁸F-FDG-PET/CT is sufficiently specific to
185 imply clinical consequences, as 70 out of 78 patients without definite NVE according to the modified Duke
186 criteria showed no increased ¹⁸F-FDG uptake around the heart valves. The results of our study are in line with
187 three other studies performed on the value of ¹⁸F-FDG-PET/CT in NVE. These studies, mainly focusing on PVE
188 with inclusion of only 6 [7] and 7 [8,9] patients with NVE, found very low sensitivity for ¹⁸F-FDG-PET/CT in
189 NVE. Previously, we performed a prospectively included study on the value of ¹⁸F-FDG-PET/CT in 72 patients
190 with suspected endocarditis of whom 66 patients had suspected NVE [10]. In this study, an older generation
191 PET/CT scanner was used and no low carbohydrate-fat allowed diet was performed. In the present study, the
192 level of agreement between two evaluating nuclear medicine physicians was much higher than in the previous
193 study (0.97 versus 0.36). This difference is probably explained by the increasing experience in evaluating ¹⁸F-
194 FDG-PET/CT in NVE since this previous study and our multidisciplinary meeting performed weekly since 2013.

195

196 NVE is a clinical diagnosis that is based on risk factors, physical examination, microbiological results, and
197 imaging. The fact that diagnosing NVE is challenging, is shown by the limited sensitivity of the modified Duke
198 criteria [2], which remain the 'gold standard' for diagnosis. Also, a large percentage of suspected NVE cases
199 remains as possible NVE [11]. Therefore, patients with suspected NVE should be discussed in a
200 multidisciplinary endocarditis team, to incorporate as much individualized information as possible in the final
201 diagnosis. Our results show that by multidisciplinary consensus definite NVE was diagnosed twice as often
202 compared to diagnosis according to the modified Duke criteria and also the discouraging diagnosis of possible
203 NVE was abandoned. ¹⁸F-FDG-PET/CT is an imaging technique that should be assessed within the clinical
204 context of patients. Reevaluation of ¹⁸F-FDG-PET/CT without knowledge of clinical details which is common in
205 this type of studies, could lead to less sensitive reading.

206

207 The diagnostic value of ^{18}F -FDG-PET/CT for PVE has been extensively studied with promising results [4] and
208 ^{18}F -FDG-PET/CT was recently added to the European Society of Cardiology modified diagnostic criteria for
209 PVE [5]. Because of its relatively high specificity, adding ^{18}F -FDG-PET/CT to the Duke criteria also for NVE
210 could be valuable, as our results show an increase of NVE diagnoses when ^{18}F -FDG-PET/CT is included (Table
211 2). Three patients with rejected NVE according to the modified Duke criteria and increased ^{18}F -FDG uptake of
212 the heart valves were at high risk for NVE and could have been incorrectly diagnosed as rejected NVE. The fact
213 that TTE only, and thus no TEE, was performed in the majority of patients with possible or rejected NVE (Table
214 1), could have led to missed diagnoses of definite NVE. The diagnostic criteria of the European Society of
215 Cardiology from 2015 recommends cardiac CT in suspected NVE [5]. In our study, we did not perform cardiac
216 CT as part of our diagnostic protocol in NVE, partly due to the fact that patients were included from 2013 in the
217 present study.

218

219 Besides intra-cardiac lesions, the value of ^{18}F -FDG-PET/CT has been studied on extra-cardiac complications of
220 endocarditis. ^{18}F -FDG-PET/CT has proven to be valuable and cost-effective in detecting metastatic foci in
221 patients with bacteremia and PVE and/or NVE [12,13,14] and is therefore increasingly used in patients with
222 suspected endocarditis. In our study, metastatic infection other than endocarditis was detected by ^{18}F -FDG-
223 PET/CT in 54.5% of patients, which is comparable to previous results [13,14].

224

225 A possible explanation for the limited sensitivity of ^{18}F -FDG-PET/CT in diagnosing NVE is continuous
226 movement of the cardiac valves during acquisition and the small size of vegetations, as metabolism in very small
227 vegetations could be insufficient to be discernible above background activity, especially after being blurred by
228 the movement of the heart [5]. Also, in the subacute-chronic phase of vegetations, microorganisms may
229 disappear and granulomatous inflammation occurs with transformation of vegetations into calcified deposits
230 [15]. So, a subacute course of NVE could decrease the sensitivity of ^{18}F -FDG-PET/CT as ^{18}F -FDG accumulates
231 particularly in activated leukocytes. Gomes et al. [4] proposed a diagnostic algorithm in suspected infective
232 endocarditis. The authors state that patients with highly suspected NVE should undergo both TEE and MDCTA
233 (electrocardiogram-gated multidetector CT angiography) to image intra-cardiac lesions, and also ^{18}F -FDG-
234 PET/CT for detecting extra-cardiac foci and for intra-cardiac lesions in case of sustained suspicion of NVE after
235 inconclusive TEE and MDCTA. ^{18}F -FDG is not a specific tracer, as ^{18}F -FDG uptake could also increase in
236 atherosclerotic plaques in the heart or physiological uptake in the myocardium and papillary muscles. Leukocyte

237 scintigraphy with SPECT/CT is known for a high specificity in detection of infectious foci and its value has been
238 investigated in PVE and CIED infection [16,17]. More specific PET/CT tracers, additional heparin
239 preadministration [6], motion correction, ECG-gated scanning, respiratory gated scanning to reduce breathing
240 motion artifacts, and/or combination with MDCTA, potentially optimize the diagnostic performance of PET/CT
241 to detect NVE.

242

243 Limitations of this study are the retrospective study design and the small number of patients with definite native
244 valve endocarditis according to the modified Duke criteria. In our cohort of 88 patients, 48 patients were
245 classified as possible NVE according to the modified Duke criteria. However, despite these small number of
246 patients with definite NVE this is the largest study so far on patients with native valve endocarditis. Due to our
247 study design, the comparison between ^{18}F -FDG-PET/CT and the multidisciplinary consensus could have led to
248 incorporation bias, due to the fact that ^{18}F -FDG-PET/CT is a part of the multidisciplinary consensus.

249

250 In conclusion, a negative ^{18}F -FDG-PET/CT result should not be interpreted as an exclusion of NVE. In patients
251 with possible or rejected NVE according to the modified Duke criteria, ^{18}F -FDG-PET/CT could be used in case
252 of sustained suspicion of NVE due to its high specificity in case of abnormal FDG-uptake at the valve region. In
253 patients suspected of NVE, ^{18}F -FDG-PET/CT is important for detecting metastatic infection which already
254 warrants the need to perform ^{18}F -FDG-PET/CT in all patients with NVE.

255 **Acknowledgement**

256

257 We would like to thank dr. M.J.R. Janssen for his help on obtaining data.

258 **References**

259

260 1. Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG Jr, Bayer AS, et al. Clinical presentation,
261 etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on
262 Endocarditis-Pro prospective Cohort Study. *Arch Intern Med* 2009;169:463-73.

263

264 2. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modifications to the Duke
265 criteria for the diagnosis of infective endocarditis. *Clin Infect Dis* 2000;30:633-8.

266

267 3. Habib G, Badano L, Tribouilloy C, Vilacosta I, Zamorano JL, Galderisi M, et al. Recommendations for
268 the practice of echocardiography in infective endocarditis. *Eur J Echocardiogr* 2010;11:202-19.

269

270 4. Gomes A, Glaudemans AW, Touw DJ, van Melle JP, Willems TP, Maass AH, et al. Diagnostic value of
271 imaging in infective endocarditis: a systematic review. *Lancet Infect Dis* 2017;17:e1-e14.

272

273 5. Habib G, Lancellotti P, Antunes MJ, Bongiorgi MG, Casalta JP, Del Zotti F, et al. 2015 ESC Guidelines
274 for the management of infective endocarditis: The Task Force for the Management of Infective
275 Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for
276 Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur*
277 *Heart J* 2015;36:3075-128.

278

279 6. Scholtens AM, Verberne HJ, Budde RP, Lam MG. Additional Heparin Preadministration Improves
280 Cardiac Glucose Metabolism Suppression over Low-Carbohydrate Diet Alone in (18)F-FDG PET
281 Imaging. *J Nucl Med* 2016;57:568-73.

282

283 7. Granados U, Fuster D, Pericas JM, Llopis JL, Ninot S, Quintana E, et al. Diagnostic Accuracy of 18F-
284 FDG PET/CT in Infective Endocarditis and Implantable Cardiac Electronic Device Infection: A Cross-
285 Sectional Study. *J Nucl Med* 2016;57:1726-32.

286


- 287 8. Salomaki SP, Saraste A, Kemppainen J, Bax JJ, Knuuti J, Nuutila P, et al. 18F-FDG positron emission
288 tomography/computed tomography in infective endocarditis. *J Nucl Cardiol* 2017;24:195-206.
289
- 290 9. Ricciardi A, Sordillo P, Ceccarelli L, Maffongelli G, Calisti G, Di Pietro B, et al. 18-Fluoro-2-
291 deoxyglucose positron emission tomography-computed tomography: an additional tool in the diagnosis
292 of prosthetic valve endocarditis. *Int J Infect Dis* 2014;28:219-24.
293
- 294 10. Kouijzer IJ, Vos FJ, Janssen MJ, van Dijk AP, Oyen WJ, Bleeker-Rovers CP. The value of 18F-FDG
295 PET/CT in diagnosing infectious endocarditis. *Eur J Nucl Med Mol Imaging* 2013;40:1102-7.
296
- 297 11. Habib G, Derumeaux G, Avierinos JF, Casalta JP, Jamal F, Volot F, et al. Value and limitations of the
298 Duke criteria for the diagnosis of infective endocarditis. *J Am Coll Cardiol* 1999;33:2023-9.
299
- 300 12. Orvin K, Goldberg E, Bernstine H, Groshar D, Sagie A, Kornowski R, et al. The role of FDG-PET/CT
301 imaging in early detection of extra-cardiac complications of infective endocarditis. *Clin Microbiol*
302 2015;21:69-76.
303
- 304 13. Kestler M, Munoz P, Rodriguez-Creixems M, Rotger A, Jiminez-Requena F, Mari A, et al. Role of
305 (18)F-FDG PET in Patients with Infectious Endocarditis. *J Nucl Med* 2014;55:1093-8.
306
- 307 14. Vos FJ, Bleeker-Rovers CP, Sturm PD, Krabbe PF, van Dijk AP, Cuijpers ML, et al. 18F-FDG PET/CT
308 for detection of metastatic infection in gram-positive bacteremia. *J Nucl Med* 2010;51:1234-40.
309
- 310 15. Thiene G, Basso C. Pathology and pathogenesis of infective endocarditis in native heart valves.
311 *Cardiovasc Pathol* 2006;15:256-63.
312
- 313 16. Rouzet F, Chequer R, Benali K, Lepage L, Ghodbane W, Duval X, et al. Respective performance of
314 18F-FDG PET and radiolabeled leukocyte scintigraphy for the diagnosis of prosthetic valve
315 endocarditis. *J Nucl Med* 2014;55:1980-5.
316

317 17. Erba PA, Conti U, Lazzeri E, Sollini M, Doria R, De Tommasi SM, et al. Added value of ^{99m}Tc-
318 HMPAO-labeled leukocyte SPECT/CT in the characterization and management of patients with
319 infectious endocarditis. *J Nucl Med* 2012;53:1235-43.

320 **Figures**

321

322



323


324 **Fig. 1** ^{18}F -FDG-PET/CT images of a 79-year-old man who was admitted with fever and positive blood cultures

325 with *Streptococcus gallolyticus*. Besides spondylodiscitis of Th8-9 and L3-4, ^{18}F -FDG-PET/CT showed

326 increased ^{18}F -FDG uptake of the mitral valve (arrow). TEE was negative for endocarditis. Although this patient

327 had only possible endocarditis according to the modified Duke criteria, he was treated as having NVE

328



329

330 **Fig. 2** ^{18}F -FDG-PET/CT images of a 75-year-old woman with a pacemaker and ovarian carcinoma who was
331 admitted with fever and severe confusion. Blood cultures grew *Proteus mirabilis*. TEE was negative for
332 endocarditis. ^{18}F -FDG-PET/CT showed highly increased ^{18}F -FDG uptake of the mitral valve (arrow). A few days
333 later she developed splinter hemorrhages on her hand and foot. TEE was repeated one week after the ^{18}F -FDG-
334 PET/CT and confirmed the diagnosis of native mitral valve endocarditis, no vegetations were seen on her
335 pacemaker leads. This patients died one week later due to therapy-resistant mitral valve endocarditis

336 **Tables**

337

338 **Table 1.** Baseline characteristics of all 88 patients with definite, possible, and rejected NVE according to the
 339 modified Duke criteria

	Definite endocarditis	Possible endocarditis	Rejected endocarditis
Number of patients	10	48	30
Male (%)	6 (60.0)	28 (58.3)	16 (53.3)
Mean age in years (range)	68.9 (35 - 90)	63.4 (21 - 88)	54.5 (17 - 88)
Blood culture positive (%)	10 (100)	48 (100)	30 (100)
<i>S. aureus</i> (%)	3 (30.0)	40 (83.3)	13 (43.3)
<i>Coagulase-negative</i>	0	1 (2.1)	1 (3.3)
<i>Staphylococcus</i> (%)			
<i>Streptococcus</i> (%)	5 (50.0)	5 (10.4)	3 (10.0)
<i>Enterococcus</i> (%)	2 (20.0)	1 (2.1)	1 (3.3)
<i>Gram-negative</i> (%)	0	1 (2.1)	10 (33.3)
Other (%)	0	0	2 (6.7)
Pacemaker (%)	2 (20.0)	4 (8.3)	0
ICD ¹ (%)	0	1 (2.1)	0
Echocardiography			
TTE ² only (%)	2 (20.0)	19 (39.6)	23 (76.7)
TEE ³ only (%)	3 (30.0)	2 (4.2)	2 (6.7)
Both TTE and TEE (%)	5 (50.0)	27 (56.3)	5 (16.7)
Metastatic infection other than endocarditis (%)	8 (80.0)	30 (62.5)	10 (33.3)

340 ¹ ICD: implantable cardioverter defibrillator.

341 ² TTE: transthoracic echocardiography.

342 ³ TEE: transesophageal echocardiography

343 **Table 2.** Diagnosis of NVE according to the modified Duke criteria, the modified Duke criteria including ¹⁸F-
 344 FDG-PET/CT, revised ¹⁸F-FDG-PET/CT result only, and diagnosis by multidisciplinary consensus

	Modified Duke criteria (%)	Modified Duke criteria including ¹⁸ F-FDG-PET/CT (%)	Revised ¹⁸ F-FDG-PET/CT result only (%)	Multidisciplinary consensus ¹
(n=88)				
Definite	10 (11.4)	18 (20.5)	11 (12.5)	20 (22.7)
Possible	48 (54.5)	43 (48.9)	0	0
Rejected	30 (34.1)	27 (30.7)	77 (87.5)	68 (77.3)

345 ¹ Multidisciplinary board including infectious diseases specialists, medical microbiologists, cardiologists, nuclear
 346 medicine physicians, and if needed cardiac surgeons.